Until now, no dose-limiting toxicities (DLTs) have been observed across all evaluated dose levels (80–1000 μg/kg weekly) in the 30 enrolled R/R MM patients (median of 8 prior lines of therapy, 87% triple-class refractory) of which seven patients had received prior BCMA-targeted therapy [37,65]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.